Zoetis Inc (ZTS)
194.81
-0.06
(-0.03%)
USD |
NYSE |
Sep 27, 16:00
194.91
+0.10
(+0.05%)
After-Hours: 20:00
Zoetis SG&A Expense (TTM): 2.218B for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 2.218B |
March 31, 2024 | 2.193B |
December 31, 2023 | 2.151B |
September 30, 2023 | 2.10B |
June 30, 2023 | 2.076B |
March 31, 2023 | 2.049B |
December 31, 2022 | 2.009B |
September 30, 2022 | 2.088B |
June 30, 2022 | 2.091B |
March 31, 2022 | 2.057B |
December 31, 2021 | 2.001B |
September 30, 2021 | 1.928B |
June 30, 2021 | 1.848B |
March 31, 2021 | 1.746B |
December 31, 2020 | 1.726B |
September 30, 2020 | 1.678B |
June 30, 2020 | 1.645B |
March 31, 2020 | 1.658B |
December 31, 2019 | 1.638B |
September 30, 2019 | 1.586B |
June 30, 2019 | 1.562B |
March 31, 2019 | 1.515B |
December 31, 2018 | 1.484B |
September 30, 2018 | 1.425B |
June 30, 2018 | 1.386B |
Date | Value |
---|---|
March 31, 2018 | 1.363B |
December 31, 2017 | 1.334B |
September 30, 2017 | 1.334B |
June 30, 2017 | 1.351B |
March 31, 2017 | 1.358B |
December 31, 2016 | 1.364B |
September 30, 2016 | 1.428B |
June 30, 2016 | 1.457B |
March 31, 2016 | 1.493B |
December 31, 2015 | 1.532B |
September 30, 2015 | 1.604B |
June 30, 2015 | 1.624B |
March 31, 2015 | 1.641B |
December 31, 2014 | 1.643B |
September 30, 2014 | 1.604B |
June 30, 2014 | 1.609B |
March 31, 2014 | 1.612B |
December 31, 2013 | 1.613B |
September 30, 2013 | 1.608B |
June 30, 2013 | 1.544B |
March 31, 2013 | 1.489B |
December 31, 2012 | 1.47B |
September 30, 2012 | 1.444B |
June 30, 2012 | 1.44B |
March 31, 2012 | 1.456B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
1.586B
Minimum
Sep 2019
2.218B
Maximum
Jun 2024
1.924B
Average
2.005B
Median
SG&A Expense (TTM) Benchmarks
Pfizer Inc | 15.07B |
Alnylam Pharmaceuticals Inc | 856.49M |
Biomarin Pharmaceutical Inc | 987.94M |
Corcept Therapeutics Inc | 215.62M |
Ionis Pharmaceuticals Inc | 258.76M |